Based on the CROWN Findings, Lorlatinib Should Be the Preferred First-Line Treatment for Patients With Advanced ALK-Positive NSCLC
- Author(s)
- Hoe, HJ; Solomon, BJ;
- Details
- Publication Year 2025,Volume 20,Issue #2,Page 154-156
- Journal Title
- Journal of Thoracic Oncology
- Publication Type
- Commentary
- Publisher
- Elsevier
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.1016/j.jtho.2024.10.018
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-02-11 06:48:53
Last Modified: 2025-02-11 06:50:53